0
Signin
countryflagUS

18889881171

AAPL 183.36 5.9701% MSFT 406.8 2.2522% GOOG 169.01 0.3265% GOOGL 167.21 0.3541% AMZN 186.235 0.8202% NVDA 887.83 3.4562% META 452.05 2.3479% TSLA 181.14 0.6277% TSM 141.56 3.9125% LLY 734.97 -2.7702% V 268.47 0.3214% AVGO 1278.11 3.1924% JPM 190.51 -0.6% UNH 492.45 -0.1055% NVO 123.05 -0.7821% WMT 59.82 0.1842% LVMUY 168.5 2.1584% XOM 116.02 -0.1893% LVMHF 841.0 1.8789% MA 443.58 0.5622%

Third Harmonic Bio Inc.

Healthcare US THRD

11.7USD
0.11(0.95%)

Last update at 2024-05-03T20:00:00Z

Day Range

11.5411.85
LowHigh

52 Week Range

3.7511.53
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -35.15500M -29.60900M -12.80800M
Minority interest - - -
Net income -37.70800M -29.60900M -12.80700M
Selling general administrative 13.30M 3.26M 1.17M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation - - -
Ebit 37.71M -19.00400M -11.11900M
Ebitda -37.70800M -19.00400M -11.12000M
Depreciation and amortization -2.55200M -10.60500M -0.00100M
Non operating income net other - - -
Operating income -37.70800M -19.00400M -11.11900M
Other operating expenses 37.71M 19.00M 11.12M
Interest expense 2.55M 10.61M -
Tax provision - - -
Interest income - - -
Net interest income - - -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 2.55M 10.61M -0.00100M
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses 37.71M 19.00M 11.12M
Cost of revenue - - -
Total other income expense net 2.55M -10.60500M -1.68900M
Discontinued operations - - -
Net income from continuing ops -35.15500M -29.60900M -12.80800M
Net income applicable to common shares - -29.60900M -12.80700M
Preferred stock and other adjustments - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Total assets 298.68M 129.16M 8.43M
Intangible assets - - -
Earning assets - - -
Other current assets 3.96M 0.88M 0.16M
Total liab 9.61M 175.87M 26.79M
Total stockholder equity 289.07M -46.70600M -18.35700M
Deferred long term liab - - -
Other current liab 3.18M 3.89M 1.63M
Common stock 0.00400M 0.00100M 0.00100M
Capital stock 0.00400M 0.00100M 0.00100M
Retained earnings -83.39600M -48.24100M -18.63200M
Other liab - - 5.88M
Good will - - -
Other assets 1.48M - -
Cash 288.88M 128.28M 8.28M
Cash and equivalents - - -
Total current liabilities 5.65M 5.69M 2.21M
Current deferred revenue - - -
Net debt -284.53800M -128.28000M -8.27700M
Short term debt 0.39M - -
Short long term debt - - -
Short long term debt total 4.34M - -
Other stockholder equity 73.78M 1.53M 0.27M
Property plant equipment - - -
Total current assets 292.83M 129.16M 8.43M
Long term investments - - -
Net tangible assets - -46.70600M -18.35700M
Short term investments - - -
Net receivables - - -
Long term debt - - -
Inventory - - -
Accounts payable 2.09M 1.80M 0.58M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other 1.48M - -
Deferred long term asset charges - - -
Non current assets total 5.84M 0.00000M 0.00000M
Capital lease obligations 4.34M - -
Long term debt total - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -0.03600M 0.00000M 0.00000M
Change to liabilities 0.00000M 1.22M 0.32M
Total cashflows from investing activities -0.03600M -0.03600M -0.03600M
Net borrowings - - -
Total cash from financing activities 195.99M 135.75M 10.82M
Change to operating activities -4.84100M 1.53M 1.41M
Net income -35.15500M -29.60900M -12.80700M
Change in cash 161.04M 120.00M 1.64M
Begin period cash flow 128.28M 8.28M 6.64M
End period cash flow 289.32M 128.28M 8.28M
Total cash from operating activities -34.91700M -15.74600M -9.18700M
Issuance of capital stock 198.18M 135.75M 10.82M
Depreciation 0.00100M - -
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities -2.18700M 135.75M 10.82M
Change to netincome 4.79M 11.12M 1.88M
Capital expenditures 0.04M 0.04M 0.04M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital -4.55100M 2.74M 1.74M
Stock based compensation 4.75M 0.51M 0.20M
Other non cash items 0.04M 10.61M 1.69M
Free cash flow -34.95300M -15.74600M -9.18700M

Fundamentals

  • Previous Close 11.59
  • Market Cap459.33M
  • Volume70464
  • P/E Ratio14.97
  • Dividend Yield-%
  • EBITDA-37.70700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM0.76

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
THRD
Third Harmonic Bio Inc.		 0.11 0.95% 11.70 14.97 - - 1.56 -3.3391
NVO
Novo Nordisk A/S		 -0.97 0.78% 123.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.71 2.18% 121.51 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.92 0.23% 401.08 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.14 0.15% 91.19 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Third Harmonic Bio Inc.

300 Technology Square, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Ms. Natalie C. Holles CEO & Director 1973
Mr. Robert Ho Chief Financial Officer 1975
Mr. Adrian S. Ray Ph.D. Chief Scientific Officer 1976
Ms. Julie Person Chief Admin. Officer 1973
Mr. Gregg Keaney Ph.D. Sr. VP of Product Devel. NA
Mr. Steven P. Sweeney Sr. VP of Devel. Operations NA
Dr. Edward R. Conner M.D. Chief Medical Officer 1973
Ommer Chohan Treasurer & Sec. NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).